New Angiex LinkedIn Series – Please Follow Us!

Posted by on July 26, 2026 9 comments

Dear PHD readers,

As you know we’ve been away from the site for a long time building our cancer therapy company, Angiex. Angiex’s drug AGX101 is now in the clinic and we have an exciting story to tell, which will be unfolding on LinkedIn. Please follow the company and help us spread the word. The world needs to know that something special is coming for cancer patients!

I will add LinkedIn posts to this as they come out. Here is what has been published so far:

  1. Angiex’s vision: No one should die of cancer
  2. Our founders’ biological discoveries
  3. Our mission: Create a transformative ADC
  4. From biological discovery to AGX101

To help us, please go to each post and click “Re-post” adding your own thoughts. Also, please connect with me on LinkedIn. Thank you!

Please feel free to contact me if you would like to know more about Angiex or think you may be able to help us. The best way to contact me is through the email addresses on the Angiex Contact page. Cancer patients can learn about clinical trial opportunities at our Clinical Trial Q&A page.

Best, Paul

This is a sticky post! continue reading?

Angiex – good news coming for cancer patients

Posted by on November 1, 2026 No comments

Hi everyone,

Bret asked in the comments whether Angiex’s drug AGX101 works for Stage 4 lung cancer patients. AGX101 is in Phase 1 clinical trials and we still have a lot to learn about it. But early results are very promising. I thought I’d copy my answer here. Let me know if there is interest from PHD readers for a webinar to learn more.

Hi Bret,

Yes. AGX101 has potent on-tumor activity against all solid cancers, and so far our best results have been in lung tumors. We’ve dosed 38 patients total and 13 have had lung tumors as target lesions. The number of lung tumors treated is 24 target lesions (i.e. measured in size by the radiologist) and a similar number of non-target lesions. To date those have been metastases from other cancers rather than primary tumors, but it doesn’t really matter whether the tumors are primary or metastatic, they respond the same.

Here is an example. This is a fused PET-CT image with CT on the gray scale and PET in color.

The way our drug works is to attack both the tumor blood vessels and the tumor cells. Eliminating the blood vessels generates a coagulative necrosis that heals by scarring, while killing the tumor cells reduces metabolic activity and prevents spread of any tumor cells out of the tumor. As a result, the “success signal” is stable lesion size on CT with reduction in metabolic activity on FDG-PET. You see that success signal achieved in the linked image.

We believe that at the optimal dosing regimen we may achieve this success signal in most tumors of most solid cancer patients. We’re homing in on that dosing regimen now.

You can write me at one of the emails on the Angiex contact page, https://angiex.com/contact, for more information.

Best, Paul

Please join us! “Fireside chat” webinar tomorrow with Angiex founders

Posted by on October 29, 2024 6 comments

Dear readers,

Please join me Wednesday at 4 pm Eastern with famed scientist, angiogenesis expert, discoverer of VEGF, and Angiex co-founder Dr. Harold Dvorak in an online Fireside Chat.

We’ll discuss Hal’s pathbreaking work in angiogenesis; the efforts of Hal and his collaborators to develop a universal therapy for all solid cancers by attacking the tumor vasculature; and the prospects for achieving such a universal therapy through antibody-drug conjugate therapies directed against the protein TM4SF1.

We’ll look at the process of discovering TM4SF1’s amazing biology and building Angiex; and the state of Angiex’s lead drug AGX101, now showing promising early results in Phase 1 clinical trials for all solid cancers.

Please join us for a fascinating discussion of science, entrepreneurship, and the effort to fulfill Angiex’s vision that “No One Should Die of Cancer!”

Link: https://www.linkedin.com/events/angiex-inc-livewebinar7254915501640892416/

Angiex Doses First Patient in Clinical Trial of AGX101!

Posted by on August 7, 2024 15 comments

I’m pleased to announce that Angiex has dosed the first patient in our Phase 1 clinical trial of AGX101, Angiex’s lead drug.

As some of you know, 9 years ago Shou-Ching and I suspended our blog and health retreat to create Angiex. It’s been a busy and exciting nine years, and I’m looking forward to telling you about the special biology Shou-Ching discovered and the drug we’ve made in the weeks ahead.

But for today, I’m happy to simply savor the accomplishment of finally having the opportunity to test what we’ve made in clinical cancer patients. This is the fruit of 20 years of biology research and 12 years of drug development. Please keep an eye out for upcoming posts, and say a prayer for the success of Angiex and the cancer patients we are treating.

Some links:

AGX101 first patient dosed